Funding for this research was provided by:
Canadian Institutes of Health Research (340674)
Received: 16 January 2020
Accepted: 16 September 2020
First Online: 15 October 2020
Ethics approval and consent to participate
: Mice were handled in accordance with the AUP 1542 approved by the University Health Network Animal Care Committee and in accordance with the CCAC regulations.
: Not applicable.
: ACN has received clinical trial funding from Novartis for a Window of Opportunity Trial using alpelisib in HNSCC patients (NCT03138070).